• 1
    Kaipiainen-Seppanen O, Savolainen A. Incidence of chronic juvenile rheumatic diseases in Finland during 1980-1990. Clin Exp Rheumatol 1996; 14: 4414.
  • 2
    Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990; 17: 132934.
  • 3
    Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34: 7326.
  • 4
    Spencer CH, Hanson V, Singsen BH, Bernstein BH, Kornreich HK, King KK. Course of treated juvenile dermatomyositis. J Pediatr 1984; 105: 399408.
  • 5
    Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 5419.
  • 6
    Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103: 8828.
  • 7
    Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985; 12: 11408.
  • 8
    Baron M, Small P. Polymyositis/dermatomyositis: clinical features and outcome in 22 patients. J Rheumatol 1985; 12: 2836.
  • 9
    Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 2343.
  • 10
    Wallace CA. The use of methotrexate in childhood rheumatic diseases [review]. Arthritis Rheum 1998; 41: 38191.
  • 11
    Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al, and the Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. N Engl J Med 1992; 326: 10439.
  • 12
    Reed AM, Lopez M. Juvenile dermatomyositis: recognition and treatment. Paediatr Drugs 2002; 4: 31521.
  • 13
    Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992; 35: 11439.
  • 14
    Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000; 19: 13841.
  • 15
    Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41: 3929.
  • 16
    Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94: 37987.
  • 17
    Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47: 50511.
  • 18
    Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 2002; 28: 83357.
  • 19
    Wulffraat N, Elst E, Pilkington C, for the PRES Working Group of JDM. Initial treatment of JDM: a survey among PRINTO members. Proceedings of the 10th European Pediatric Rheumatology Congress, Annual Scientific Meeting of PRES; 2003 Oct 2–5; Stresa, Italy.
  • 20
    Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 4037.
  • 21
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 3447.
  • 22
    Feldman BM, Ayling-Campos A, Luy L, Stevens D, Silverman ED, Laxer RM. Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol 1995; 22: 32631.
  • 23
    Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, et al, and the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. J Rheumatol 2001; 28: 110611.
  • 24
    Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498502.
  • 25
    Medical Research Council. Aids to the examination of the peripheral nervous system. 3rd ed. Eastbourne (UK): Bailliere Tindall; 1986. Memorandum no. 45.
  • 26
    Helewa A, Goldsmith CH, Smythe HA. The modified sphygmomanometer: an instrument to measure muscle strength: a validation study. J Chronic Dis 1981; 34: 35361.
  • 27
    Helewa A, Goldsmith CH, Smythe HA. Patient, observer and instrument variation in the measurement of strength of shoulder abductor muscles in patients with rheumatoid arthritis using a modified sphygmomanometer. J Rheumatol 1986; 13: 10449.
  • 28
    Singsen BH, Goldbach-Mansky R. Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum Dis Clin North Am 1997; 23: 81140.
  • 29
    Miller JJ III, Koehler JP. Persistence of activity in dermatomyositis of childhood. Arthritis Rheum 1977; 20 Suppl 2: 3327.
  • 30
    Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 1987; 30: 32834.
  • 31
    Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27: 2498503.